Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

OpRegen

Source date not recordedAnalyse record ↗

Retinal pigment epithelial cell-replacement therapy in a recruiting Phase 2a study for geographic atrophy from dry AMD.

Modality
allogeneic pluripotent-stem-cell-derived retinal pigment epithelial cell replacement therapy
Availability (US)
Phase 2a GAlette study Recruiting
Biomarkers
procedure-related adverse events; successful subretinal delivery; optical-coherence-tomography retinal structure; best-corrected visual acuity
Hallmark targeted
stem cell exhaustion, impaired tissue regeneration, age-related retinal degeneration
Kind
investigational cell therapy
Clinical trials
NCT05626114 — Phase 2, Recruiting on September 15, 2026 registry update; NCT02286089 — Phase 1/Phase 2, Active, not recruiting on July 27, 2026 update